Parkinsonism-associated speech disorders

Skripkina N.A.; Arefyeva A.P.

doi:https://doi.org/10.17116/jnevro202012010261

Skripkina N.A.

Russian Medical Academy of Continuous Professional Education

Arefyeva A.P.

Russian Medical Academy of Continuous Professional Education

Parkinsonism-associated speech disorders

Authors:

Skripkina N.A., Arefyeva A.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2): 61‑66

DOI: 10.17116/jnevro202012010261

Read: 5749 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Skripkina NA, Arefyeva AP. Parkinsonism-associated speech disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2):61‑66. (In Russ.)
https://doi.org/10.17116/jnevro202012010261

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study clinical and neurophysiological features of speech disorders in PD, multisystem atrophy (MSA) and progressive supranuclear palsy (PNP).

MATERIAL AND METHODS

Thirty-one patients with PD and 14 patients with MSA and PSP were examined. The Unified rating scale for Parkinson’s disease of the International movement disorders society (MDS-UPDRS) and a neurophysiological analysis of speech disorders using acoustic spectral analysis of voice and speech according to the method of Jan Rusz et al (2004) were used.

RESULTS

Patients with PD showed a parallel increase in the severity of axial motor disorders (hypomimia, walking disorders, postural disorders) and speech disorders. Patients with MSA and PSP differ not only from the PD patients but also among themselves by clinical presentations (motor, autonomic, cognitive) and speech disorders.

CONCLUSION

The clinical and neurophysiological features of speech disorders in patients with various variants of parkinsonism will be useful in the differential diagnosis of these diseases and can be used in developing approaches to patient rehabilitation.

Keywords:

speech disorders

dysarthria

Parkinson’s disease

multisystem neurodegeneration

multisystem atrophy

progressive supranuclear palsy

acoustic spectral speech analysis

Authors:

Skripkina N.A.

Russian Medical Academy of Continuous Professional Education

Arefyeva A.P.

Russian Medical Academy of Continuous Professional Education

Received:

15.06.2020

Accepted:

04.07.2020

Close metadata

References:

Fernandez HH, Machado AG, Pandya M. A practical approach to movement disorders. 2nd ed. New York: Demos Medical Publishing; 2015.
Hunter Manasco M. Introduction to Neurogenic Communication Disorders. 2nd ed. Burlington: Jones & Bartlett Learning; 2017.
Dashtipour K, Tafreshi A, Lee J, Crawley B. Speech disorders in Parkinson’s disease: pathophysiology, medical management and surgical approaches. Neurodegenerative Disease Management. 2018;8(5):337-348. https://doi.org/10.2217/nmt-2018-0021
Johnson J. Speech, voice and communication. International Review of Neurobiology. 2017;134:1189-1205. https://doi.org/10.1016/bs.irn.2017.04.014
Fedorova NV, Tekaeva FK, Orlova OS. Speech and voice disorders and their influence on life quality of patients with Parkinson’s disease. Rossiiskaya Otorinolaringologiya. 2009;4(41):152-155. (In Russ.).
Parashos SA, Wichmann RL, Melby T. Navigating life with Parkinson’s di-sease. New York: Oxford University Press; 2013.
Hlavnicka J, Cmejla R, Tykalova T, Sonka K, Ruzicka E, Rusz J. Automa-ted analysis of connected speech reveals early biomarkers of Parkinson’s disease in patients with rapid eye movement sleep behavior disorder. Scientific Reports. 2017;7(1). https://doi.org/10.1038/s41598-017-00047-5
Rusz J, Bonnet C, Klempır J,Tykalová T, Baborová E, Novotný M, Rulseh A, Růžička E. Speech disorders reﬂect differing pathophysiology in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. Journal of Neurology. 2015;262(4):992-1001. https://doi.org/10.1007/s00415-015-7671-1
Goetz C, Tilley B, Shaftman S, Stebbins G, Fahn S, Martinez‐Martin P, Poewe W, Sampaio C, Stern M, Dodel R, Dubois R, Holloway R, Jankovic J, Kulisevsky J, Lang A, Lees A, Leurgans S, LeWitt P, Nyenhuis D, Olanow C, Rascol O, Schrag A, Teresi J, van Hilten J, LaPelle N. Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results. Movement Disorders. 2008;23(15):2129-2170. https://doi.org/10.1002/mds.22340
Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F, Lacomblez L, Bloch F, Verny M, Fermanian J, Agid Y, Ludolph AC, Leigh PN, Bensimon G; NNIPPS Study Group. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-PARKINSON PLUS SCALE. PLoS ONE. 2011;6(8):e 22293. https://doi.org/10.1371/journal.pone.0022293
Hlavnicka J, Cmejla R, Klempır J, Ruzicka E, Rusz J. Acoustic tracking of pitch, modal, and subharmonic vibrations of vocal folds in Parkinsonism. IEEE Access. 2019;7:150339-150354. https://doi.org/10.1109/access.2019.2945874
Novotny M, Rusz J, Cmejla R, Ruzicka E. Automatic evaluation of articulatory disorders in Parkinson’s disease. IEEE/ACME Transactions on Audio, Speech, and Language Proceeding. 2014;22(9):1366-1378. https://doi.org/10.1109/taslp.2014.2329734
Novotny M, Rusz J, Cmejla R, Ruzickova H, Klempir J, Ruzicka E. Hypernasality associated with basal ganglia dysfunction: Evidence from Parkinson’s disease and Huntington’s disease. Peer J. 2016;4:e2530. https://doi.org/10.7717/peerj.2530
Rusz J, Cmejla R, Ruzickova H, Ruzicka E. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. The Journal of the Acoustical Society of America. 2011;129(1):350-367. https://doi.org/10.1121/1.3514381
Rusz J, Hlavndicka J, Cmejla R, Ruzicka E. Automatic evaluation of speech rhythm instability and acceleration in dysarthrias associated with basal ganglia dysfunction. Frontiers in Bioengineering and Biotechnology. 2015;3:104. https://doi.org/10.3389/fbioe.2015.00104